VCNXVACCINEX, INC.

Nasdaq vaccinex.com


$ 5.38 $ 0.21 (3.87 %)    

Friday, 06-Sep-2024 15:58:52 EDT
QQQ $ 446.25 $ -12.35 (-2.68 %)
DIA $ 404.28 $ -3.99 (-0.98 %)
SPY $ 539.90 $ -9.25 (-1.68 %)
TLT $ 99.49 $ -0.01 (-0.01 %)
GLD $ 230.65 $ -1.72 (-0.74 %)
$ 5.63
$ 5.31 x 200
-- x --
-- - --
$ 4.21 - $ 51.98
6,105
na
9.73M
$ 0.87
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2024 06-30-2024 10-Q
2 05-15-2024 03-31-2024 10-Q
3 04-02-2024 12-31-2023 10-K
4 11-13-2023 09-30-2023 10-Q
5 08-14-2023 06-30-2023 10-Q
6 05-15-2023 03-31-2023 10-Q
7 03-31-2023 12-31-2022 10-K
8 11-14-2022 09-30-2022 10-Q
9 08-15-2022 06-30-2022 10-Q
10 05-16-2022 03-31-2022 10-Q
11 03-31-2022 12-31-2021 10-K
12 11-08-2021 09-30-2021 10-Q
13 08-16-2021 06-30-2021 10-Q
14 05-17-2021 03-31-2021 10-Q
15 03-31-2021 12-31-2020 10-K
16 11-13-2020 09-30-2020 10-Q
17 08-14-2020 06-30-2020 10-Q
18 05-14-2020 03-31-2020 10-Q
19 03-09-2020 12-31-2019 10-K
20 11-12-2019 09-30-2019 10-Q
21 08-14-2019 06-30-2019 10-Q
22 05-15-2019 03-31-2019 10-Q
23 03-13-2019 12-31-2018 10-K
24 11-13-2018 09-30-2018 10-Q
25 08-14-2018 06-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 vaccinex-granted-us-patent-12070500----use-of-semaphorin-4d-antibodies-in-combination-with-an-immune-modulating-therapy-to-inhibit-tumor-growth-and-metastasis

https://ppubs.uspto.gov/dirsearch-public/print/downloadBasicPdf/12070500?requestToken=eyJzdWIiOiJiYzJlZmQ2Zi1mMTk5LTQwZDMtOGZhN...

 vaccinex-shares-resume-trade
Vaccinex Shares Resume Trade
07/31/2024 14:11:25

 vaccinex-announces-early-stage-signal-ad-trial-results-for-pepinemab-antibody-in-alzheimers-disease-findings-show-novel-mechanism-targeting-astrocyte-activation-delays-disease-progression

Results Echo Phase 2 Huntington's Disease Study; Presented By Principal Investigator Eric Siemers, MD, At Alzheimer's A...

 vaccinex-to-report-topline-data-for-signal-ad-phase-1b2-trial-of-pepinemab-in-alzheimers-disease-at-the-alzheimers-association-international-conference-philadelphia-july-31-2024

Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer...

 vaccinex-shares-resume-trade
Vaccinex Shares Resume Trade
05/31/2024 13:43:59

 vaccinex-q1-eps-294-sales-10400k-down-from-55000k-yoy

Vaccinex (NASDAQ:VCNX) reported quarterly losses of $(2.94) per share. The company reported $104.00 thousand in sales this quar...

 vaccinex-q4-eps-033-up-from-2310-yoy

Vaccinex (NASDAQ:VCNX) reported quarterly losses of $(0.33) per share. This is a 98.57 percent increase over losses of $(23.10)...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION